We have located links that may give you full text access.
Measuring the Symptom Experience of Patients with Cancer in Indonesia: Cross-cultural Adaptation and Validation of the Memorial Symptom Assessment Scale Indonesian Version.
Journal of Pain and Symptom Management 2018 August 32
CONTEXT: Little is known about cancer-related symptoms in terms of prevalence, severity, and distress among patients with cancer in Indonesia due to a lack of a valid and reliable scale.
OBJECTIVE: to translate and validate the Memorial Symptom Assessment Scale (MSAS) among cancer patients in Indonesia.
METHODS: Two procedures consisting of forward-backward translation and validation were conducted. The validation process including pre-testing involved 34 cancer patients, and the psychometric testing of the Indonesian Version of MSAS (MSAS-I) involved 207 cancer patients. Internal consistency, test-retest reliability, construct, and concurrent validity of the MSAS-I were established.
RESULTS: Cronbach's alpha coefficients for the total scale and subscales of the MSAS-I ranged from 0.75 to 0.87. The interclass correlations for test-retest reliability ranged from 0.80 to 0.89. A two-factor structure in the MSAS-I was produced by exploratory factor analysis, and the two factors accounted for 28.34% of the cumulative variance. In addition, the concurrent validity was demonstrated by the significant associations between the subscales of the MSAS-I and their corresponding subscales in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C 30, with r = -0.25 to -0.65 (all p < 0.001).
CONCLUSION: The MSAS-I presents a valid and reliable scale for assessing symptom frequency, severity, and distress among patients with cancer in Indonesia.
IMPLICATION FOR NURSING: The MSAS-I can assess physical and psychological symptoms during cancer treatment. In addition, the MSAS-I may facilitate in measuring the effectiveness of symptom management strategies.
OBJECTIVE: to translate and validate the Memorial Symptom Assessment Scale (MSAS) among cancer patients in Indonesia.
METHODS: Two procedures consisting of forward-backward translation and validation were conducted. The validation process including pre-testing involved 34 cancer patients, and the psychometric testing of the Indonesian Version of MSAS (MSAS-I) involved 207 cancer patients. Internal consistency, test-retest reliability, construct, and concurrent validity of the MSAS-I were established.
RESULTS: Cronbach's alpha coefficients for the total scale and subscales of the MSAS-I ranged from 0.75 to 0.87. The interclass correlations for test-retest reliability ranged from 0.80 to 0.89. A two-factor structure in the MSAS-I was produced by exploratory factor analysis, and the two factors accounted for 28.34% of the cumulative variance. In addition, the concurrent validity was demonstrated by the significant associations between the subscales of the MSAS-I and their corresponding subscales in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C 30, with r = -0.25 to -0.65 (all p < 0.001).
CONCLUSION: The MSAS-I presents a valid and reliable scale for assessing symptom frequency, severity, and distress among patients with cancer in Indonesia.
IMPLICATION FOR NURSING: The MSAS-I can assess physical and psychological symptoms during cancer treatment. In addition, the MSAS-I may facilitate in measuring the effectiveness of symptom management strategies.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app